Menu
Back to Journals » Clinical Ophthalmology » Volume 8
Advances in gene therapy technologies to treat retinitis pigmentosa
Authors Petrs-Silva H, Linden R
Received 26 September 2013
Accepted for publication 5 November 2013
Published 24 December 2013 Volume 2014:8 Pages 127—136
DOI https://doi.org/10.2147/OPTH.S38041
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Hilda Petrs-Silva, Rafael Linden
Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
Abstract: Retinitis pigmentosa (RP) is a class of diseases that leads to progressive degeneration of the retina. Experimental approaches to gene therapy for the treatment of inherited retinal dystrophies have advanced in recent years, inclusive of the safe delivery of genes to the human retina. This review is focused on the development of gene therapy for RP using recombinant adenoassociated viral vectors, which show a positive safety record and have so far been successful in several clinical trials for congenital retinal disease. Gene therapy for RP is under development in a variety of animal models, and the results raise expectations of future clinical application. Nonetheless, the translation of such strategies to the bedside requires further understanding of the mutations and mechanisms that cause visual defects, as well as thorough examination of potential adverse effects.
Keywords: retinitis pigmentosa, photoreceptor, gene therapy, AAV
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.